A risk-characterization framework for decision-making at the Food and Drug Administration:
Gespeichert in:
| Körperschaft: | |
|---|---|
| Format: | Elektronisch E-Book |
| Sprache: | English |
| Veröffentlicht: |
Washington D.C.
National Academies Press
[2011]
|
| Schlagworte: | |
| Online-Zugang: | FAW01 FAW02 Volltext |
| Beschreibung: | Title from PDF t.p Description based on version viewed October 3, 2014 |
| Beschreibung: | 1 online resource (1 PDF file (xiv, 192 pages)) illustrations |
| ISBN: | 0309212804 0309212812 1283135167 9780309212809 9780309212816 9781283135160 |
Internformat
MARC
| LEADER | 00000nmm a2200000zc 4500 | ||
|---|---|---|---|
| 001 | BV043033783 | ||
| 003 | DE-604 | ||
| 005 | 00000000000000.0 | ||
| 007 | cr|uuu---uuuuu | ||
| 008 | 151120s2011 |||| o||u| ||||||eng d | ||
| 020 | |a 0309212804 |9 0-309-21280-4 | ||
| 020 | |a 0309212812 |c electronic bk. |9 0-309-21281-2 | ||
| 020 | |a 1283135167 |9 1-283-13516-7 | ||
| 020 | |a 9780309212809 |9 978-0-309-21280-9 | ||
| 020 | |a 9780309212816 |c electronic bk. |9 978-0-309-21281-6 | ||
| 020 | |a 9781283135160 |9 978-1-283-13516-0 | ||
| 035 | |a (OCoLC)741650502 | ||
| 035 | |a (DE-599)BVBBV043033783 | ||
| 040 | |a DE-604 |b ger |e rda | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-1046 |a DE-1047 | ||
| 082 | 0 | |a 353.9/970973 |2 23 | |
| 110 | 2 | |a National Academies (U.S.) |b Committee on Ranking FDA Product Categories Based on Health Consequences, Phase II |e Verfasser |4 aut | |
| 245 | 1 | 0 | |a A risk-characterization framework for decision-making at the Food and Drug Administration |c Committee on Ranking FDA Product Categories Based on Health Consequences, Phase II, Board on Environmental Studies and Toxicolgoy, Division on Earth and Life Studies, National Research Council, Institute of Medicine, National Research Council of the National Academies |
| 264 | 1 | |a Washington D.C. |b National Academies Press |c [2011] | |
| 300 | |a 1 online resource (1 PDF file (xiv, 192 pages)) |b illustrations | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b c |2 rdamedia | ||
| 338 | |b cr |2 rdacarrier | ||
| 500 | |a Title from PDF t.p | ||
| 500 | |a Description based on version viewed October 3, 2014 | ||
| 505 | 8 | |a With the responsibility to ensure the safety of food, drugs, and other products, the U.S. Food and Drug Administration (FDA) faces decisions that may have public-health consequences every day. Often the decisions must be made quickly and on the basis of incomplete information. FDA recognized that collecting and evaluating information on the risks posed by the regulated products in a systematic manner would aid in its decision-making process. Consequently, FDA and the Department of Health and Human Services (DHHS) asked the National Research Council (NRC) to develop a conceptual model that could evaluate products or product categories that FDA regulates and provide information on the potential health consequences associated with them. A Risk-Characterization Framework for Decision-Making at the Food and Drug Administration describes the proposed risk-characterization framework that can be used to evaluate, compare, and communicate the public-health consequences of decisions concerning a wide variety of products. The framework presented in this report is intended to complement other risk-based approaches that are in use and under development at FDA, not replace them. It provides a common language for describing potential public-health consequences of decisions, is designed to have wide applicability among all FDA centers, and draws extensively on the well-vetted risk literature to define the relevant health dimensions for decision-making at the FDA. The report illustrates the use of that framework with several case studies, and provides conclusions and recommendations | |
| 505 | 8 | 0 | |t Introduction -- |t A Risk-Characterization Framework -- |t Case Study of a Mitigation-Selection Decision -- |t Case Study of a Targeting Decision -- |t Case Study of a Strategic-Investment Decision -- |t Case Study of a Targeting Decision That Spans Food and Drug Administration Centers -- |t Conclusions and Future Directions -- |t Letter Report on the Development of a Model for Ranking FDA Product Categories on the Basis of Health Risks -- |t Statement of Task for the Committee on Ranking FDA Product Categories Based on Health Consequences, Phase II -- |t Scenarios Provided by the U.S. Food and Drug Administration to the Committee on Ranking FDA Product Categories Based on Health Consequences, Phase II -- |t Biographic Information on the Committee on Ranking FDA Product Categories Based on Health Consequences, Phase II -- |t Factors Hypothesized as Important in Understanding Risk |
| 610 | 1 | 4 | |a United States / Food and Drug Administration |
| 610 | 1 | 4 | |a United States / Food and Drug Administration / Management |
| 610 | 1 | 7 | |a United States / Food and Drug Administration |2 fast |
| 610 | 2 | 4 | |a United States |b Food and Drug Administration |v Case studies |
| 650 | 4 | |a Consumer Product Safety | |
| 650 | 4 | |a Risk Assessment / methods | |
| 650 | 4 | |a Decision Making | |
| 650 | 4 | |a Drug Approval | |
| 650 | 4 | |a United States Government Agencies | |
| 650 | 7 | |a POLITICAL SCIENCE / Government / State & Provincial |2 bisacsh | |
| 650 | 7 | |a Management |2 fast | |
| 650 | 7 | |a Public health |2 fast | |
| 650 | 4 | |a Decision making |z United States |v Case studies | |
| 650 | 4 | |a Product safety |z United States |x Decision making |v Case studies | |
| 650 | 4 | |a Risk assessment |z United States |v Case studies | |
| 651 | 4 | |a USA | |
| 655 | 7 | |0 (DE-588)4522595-3 |a Fallstudiensammlung |2 gnd-content | |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |a Risk-characterization framework for decision-making at the Food and Drug Administration |
| 856 | 4 | 0 | |u http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=372484 |x Aggregator |3 Volltext |
| 912 | |a ZDB-4-EBA | ||
| 999 | |a oai:aleph.bib-bvb.de:BVB01-028458430 | ||
| 966 | e | |u http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=372484 |l FAW01 |p ZDB-4-EBA |q FAW_PDA_EBA |x Aggregator |3 Volltext | |
| 966 | e | |u http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=372484 |l FAW02 |p ZDB-4-EBA |q FAW_PDA_EBA |x Aggregator |3 Volltext | |
Datensatz im Suchindex
| _version_ | 1804175392107397120 |
|---|---|
| any_adam_object | |
| author_corporate | National Academies (U.S.) Committee on Ranking FDA Product Categories Based on Health Consequences, Phase II |
| author_corporate_role | aut |
| author_facet | National Academies (U.S.) Committee on Ranking FDA Product Categories Based on Health Consequences, Phase II |
| author_sort | National Academies (U.S.) Committee on Ranking FDA Product Categories Based on Health Consequences, Phase II |
| building | Verbundindex |
| bvnumber | BV043033783 |
| collection | ZDB-4-EBA |
| contents | With the responsibility to ensure the safety of food, drugs, and other products, the U.S. Food and Drug Administration (FDA) faces decisions that may have public-health consequences every day. Often the decisions must be made quickly and on the basis of incomplete information. FDA recognized that collecting and evaluating information on the risks posed by the regulated products in a systematic manner would aid in its decision-making process. Consequently, FDA and the Department of Health and Human Services (DHHS) asked the National Research Council (NRC) to develop a conceptual model that could evaluate products or product categories that FDA regulates and provide information on the potential health consequences associated with them. A Risk-Characterization Framework for Decision-Making at the Food and Drug Administration describes the proposed risk-characterization framework that can be used to evaluate, compare, and communicate the public-health consequences of decisions concerning a wide variety of products. The framework presented in this report is intended to complement other risk-based approaches that are in use and under development at FDA, not replace them. It provides a common language for describing potential public-health consequences of decisions, is designed to have wide applicability among all FDA centers, and draws extensively on the well-vetted risk literature to define the relevant health dimensions for decision-making at the FDA. The report illustrates the use of that framework with several case studies, and provides conclusions and recommendations Introduction -- A Risk-Characterization Framework -- Case Study of a Mitigation-Selection Decision -- Case Study of a Targeting Decision -- Case Study of a Strategic-Investment Decision -- Case Study of a Targeting Decision That Spans Food and Drug Administration Centers -- Conclusions and Future Directions -- Letter Report on the Development of a Model for Ranking FDA Product Categories on the Basis of Health Risks -- Statement of Task for the Committee on Ranking FDA Product Categories Based on Health Consequences, Phase II -- Scenarios Provided by the U.S. Food and Drug Administration to the Committee on Ranking FDA Product Categories Based on Health Consequences, Phase II -- Biographic Information on the Committee on Ranking FDA Product Categories Based on Health Consequences, Phase II -- Factors Hypothesized as Important in Understanding Risk |
| ctrlnum | (OCoLC)741650502 (DE-599)BVBBV043033783 |
| dewey-full | 353.9/970973 |
| dewey-hundreds | 300 - Social sciences |
| dewey-ones | 353 - Specific fields of public administration |
| dewey-raw | 353.9/970973 |
| dewey-search | 353.9/970973 |
| dewey-sort | 3353.9 6970973 |
| dewey-tens | 350 - Public administration and military science |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>05598nmm a2200637zc 4500</leader><controlfield tag="001">BV043033783</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">00000000000000.0</controlfield><controlfield tag="007">cr|uuu---uuuuu</controlfield><controlfield tag="008">151120s2011 |||| o||u| ||||||eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">0309212804</subfield><subfield code="9">0-309-21280-4</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">0309212812</subfield><subfield code="c">electronic bk.</subfield><subfield code="9">0-309-21281-2</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">1283135167</subfield><subfield code="9">1-283-13516-7</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9780309212809</subfield><subfield code="9">978-0-309-21280-9</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9780309212816</subfield><subfield code="c">electronic bk.</subfield><subfield code="9">978-0-309-21281-6</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9781283135160</subfield><subfield code="9">978-1-283-13516-0</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)741650502</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV043033783</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rda</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-1046</subfield><subfield code="a">DE-1047</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">353.9/970973</subfield><subfield code="2">23</subfield></datafield><datafield tag="110" ind1="2" ind2=" "><subfield code="a">National Academies (U.S.)</subfield><subfield code="b">Committee on Ranking FDA Product Categories Based on Health Consequences, Phase II</subfield><subfield code="e">Verfasser</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">A risk-characterization framework for decision-making at the Food and Drug Administration</subfield><subfield code="c">Committee on Ranking FDA Product Categories Based on Health Consequences, Phase II, Board on Environmental Studies and Toxicolgoy, Division on Earth and Life Studies, National Research Council, Institute of Medicine, National Research Council of the National Academies</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Washington D.C.</subfield><subfield code="b">National Academies Press</subfield><subfield code="c">[2011]</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 online resource (1 PDF file (xiv, 192 pages))</subfield><subfield code="b">illustrations</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Title from PDF t.p</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Description based on version viewed October 3, 2014</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">With the responsibility to ensure the safety of food, drugs, and other products, the U.S. Food and Drug Administration (FDA) faces decisions that may have public-health consequences every day. Often the decisions must be made quickly and on the basis of incomplete information. FDA recognized that collecting and evaluating information on the risks posed by the regulated products in a systematic manner would aid in its decision-making process. Consequently, FDA and the Department of Health and Human Services (DHHS) asked the National Research Council (NRC) to develop a conceptual model that could evaluate products or product categories that FDA regulates and provide information on the potential health consequences associated with them. A Risk-Characterization Framework for Decision-Making at the Food and Drug Administration describes the proposed risk-characterization framework that can be used to evaluate, compare, and communicate the public-health consequences of decisions concerning a wide variety of products. The framework presented in this report is intended to complement other risk-based approaches that are in use and under development at FDA, not replace them. It provides a common language for describing potential public-health consequences of decisions, is designed to have wide applicability among all FDA centers, and draws extensively on the well-vetted risk literature to define the relevant health dimensions for decision-making at the FDA. The report illustrates the use of that framework with several case studies, and provides conclusions and recommendations</subfield></datafield><datafield tag="505" ind1="8" ind2="0"><subfield code="t">Introduction --</subfield><subfield code="t">A Risk-Characterization Framework --</subfield><subfield code="t">Case Study of a Mitigation-Selection Decision --</subfield><subfield code="t">Case Study of a Targeting Decision --</subfield><subfield code="t">Case Study of a Strategic-Investment Decision --</subfield><subfield code="t">Case Study of a Targeting Decision That Spans Food and Drug Administration Centers --</subfield><subfield code="t">Conclusions and Future Directions --</subfield><subfield code="t">Letter Report on the Development of a Model for Ranking FDA Product Categories on the Basis of Health Risks --</subfield><subfield code="t">Statement of Task for the Committee on Ranking FDA Product Categories Based on Health Consequences, Phase II --</subfield><subfield code="t">Scenarios Provided by the U.S. Food and Drug Administration to the Committee on Ranking FDA Product Categories Based on Health Consequences, Phase II --</subfield><subfield code="t">Biographic Information on the Committee on Ranking FDA Product Categories Based on Health Consequences, Phase II --</subfield><subfield code="t">Factors Hypothesized as Important in Understanding Risk</subfield></datafield><datafield tag="610" ind1="1" ind2="4"><subfield code="a">United States / Food and Drug Administration</subfield></datafield><datafield tag="610" ind1="1" ind2="4"><subfield code="a">United States / Food and Drug Administration / Management</subfield></datafield><datafield tag="610" ind1="1" ind2="7"><subfield code="a">United States / Food and Drug Administration</subfield><subfield code="2">fast</subfield></datafield><datafield tag="610" ind1="2" ind2="4"><subfield code="a">United States</subfield><subfield code="b">Food and Drug Administration</subfield><subfield code="v">Case studies</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Consumer Product Safety</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Risk Assessment / methods</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Decision Making</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drug Approval</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">United States Government Agencies</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">POLITICAL SCIENCE / Government / State & Provincial</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Management</subfield><subfield code="2">fast</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Public health</subfield><subfield code="2">fast</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Decision making</subfield><subfield code="z">United States</subfield><subfield code="v">Case studies</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Product safety</subfield><subfield code="z">United States</subfield><subfield code="x">Decision making</subfield><subfield code="v">Case studies</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Risk assessment</subfield><subfield code="z">United States</subfield><subfield code="v">Case studies</subfield></datafield><datafield tag="651" ind1=" " ind2="4"><subfield code="a">USA</subfield></datafield><datafield tag="655" ind1=" " ind2="7"><subfield code="0">(DE-588)4522595-3</subfield><subfield code="a">Fallstudiensammlung</subfield><subfield code="2">gnd-content</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="a">Risk-characterization framework for decision-making at the Food and Drug Administration</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=372484</subfield><subfield code="x">Aggregator</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-4-EBA</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-028458430</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=372484</subfield><subfield code="l">FAW01</subfield><subfield code="p">ZDB-4-EBA</subfield><subfield code="q">FAW_PDA_EBA</subfield><subfield code="x">Aggregator</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=372484</subfield><subfield code="l">FAW02</subfield><subfield code="p">ZDB-4-EBA</subfield><subfield code="q">FAW_PDA_EBA</subfield><subfield code="x">Aggregator</subfield><subfield code="3">Volltext</subfield></datafield></record></collection> |
| genre | (DE-588)4522595-3 Fallstudiensammlung gnd-content |
| genre_facet | Fallstudiensammlung |
| geographic | USA |
| geographic_facet | USA |
| id | DE-604.BV043033783 |
| illustrated | Illustrated |
| indexdate | 2024-07-10T07:15:33Z |
| institution | BVB |
| isbn | 0309212804 0309212812 1283135167 9780309212809 9780309212816 9781283135160 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-028458430 |
| oclc_num | 741650502 |
| open_access_boolean | |
| owner | DE-1046 DE-1047 |
| owner_facet | DE-1046 DE-1047 |
| physical | 1 online resource (1 PDF file (xiv, 192 pages)) illustrations |
| psigel | ZDB-4-EBA ZDB-4-EBA FAW_PDA_EBA |
| publishDate | 2011 |
| publishDateSearch | 2011 |
| publishDateSort | 2011 |
| publisher | National Academies Press |
| record_format | marc |
| spelling | National Academies (U.S.) Committee on Ranking FDA Product Categories Based on Health Consequences, Phase II Verfasser aut A risk-characterization framework for decision-making at the Food and Drug Administration Committee on Ranking FDA Product Categories Based on Health Consequences, Phase II, Board on Environmental Studies and Toxicolgoy, Division on Earth and Life Studies, National Research Council, Institute of Medicine, National Research Council of the National Academies Washington D.C. National Academies Press [2011] 1 online resource (1 PDF file (xiv, 192 pages)) illustrations txt rdacontent c rdamedia cr rdacarrier Title from PDF t.p Description based on version viewed October 3, 2014 With the responsibility to ensure the safety of food, drugs, and other products, the U.S. Food and Drug Administration (FDA) faces decisions that may have public-health consequences every day. Often the decisions must be made quickly and on the basis of incomplete information. FDA recognized that collecting and evaluating information on the risks posed by the regulated products in a systematic manner would aid in its decision-making process. Consequently, FDA and the Department of Health and Human Services (DHHS) asked the National Research Council (NRC) to develop a conceptual model that could evaluate products or product categories that FDA regulates and provide information on the potential health consequences associated with them. A Risk-Characterization Framework for Decision-Making at the Food and Drug Administration describes the proposed risk-characterization framework that can be used to evaluate, compare, and communicate the public-health consequences of decisions concerning a wide variety of products. The framework presented in this report is intended to complement other risk-based approaches that are in use and under development at FDA, not replace them. It provides a common language for describing potential public-health consequences of decisions, is designed to have wide applicability among all FDA centers, and draws extensively on the well-vetted risk literature to define the relevant health dimensions for decision-making at the FDA. The report illustrates the use of that framework with several case studies, and provides conclusions and recommendations Introduction -- A Risk-Characterization Framework -- Case Study of a Mitigation-Selection Decision -- Case Study of a Targeting Decision -- Case Study of a Strategic-Investment Decision -- Case Study of a Targeting Decision That Spans Food and Drug Administration Centers -- Conclusions and Future Directions -- Letter Report on the Development of a Model for Ranking FDA Product Categories on the Basis of Health Risks -- Statement of Task for the Committee on Ranking FDA Product Categories Based on Health Consequences, Phase II -- Scenarios Provided by the U.S. Food and Drug Administration to the Committee on Ranking FDA Product Categories Based on Health Consequences, Phase II -- Biographic Information on the Committee on Ranking FDA Product Categories Based on Health Consequences, Phase II -- Factors Hypothesized as Important in Understanding Risk United States / Food and Drug Administration United States / Food and Drug Administration / Management United States / Food and Drug Administration fast United States Food and Drug Administration Case studies Consumer Product Safety Risk Assessment / methods Decision Making Drug Approval United States Government Agencies POLITICAL SCIENCE / Government / State & Provincial bisacsh Management fast Public health fast Decision making United States Case studies Product safety United States Decision making Case studies Risk assessment United States Case studies USA (DE-588)4522595-3 Fallstudiensammlung gnd-content Erscheint auch als Druck-Ausgabe Risk-characterization framework for decision-making at the Food and Drug Administration http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=372484 Aggregator Volltext |
| spellingShingle | A risk-characterization framework for decision-making at the Food and Drug Administration With the responsibility to ensure the safety of food, drugs, and other products, the U.S. Food and Drug Administration (FDA) faces decisions that may have public-health consequences every day. Often the decisions must be made quickly and on the basis of incomplete information. FDA recognized that collecting and evaluating information on the risks posed by the regulated products in a systematic manner would aid in its decision-making process. Consequently, FDA and the Department of Health and Human Services (DHHS) asked the National Research Council (NRC) to develop a conceptual model that could evaluate products or product categories that FDA regulates and provide information on the potential health consequences associated with them. A Risk-Characterization Framework for Decision-Making at the Food and Drug Administration describes the proposed risk-characterization framework that can be used to evaluate, compare, and communicate the public-health consequences of decisions concerning a wide variety of products. The framework presented in this report is intended to complement other risk-based approaches that are in use and under development at FDA, not replace them. It provides a common language for describing potential public-health consequences of decisions, is designed to have wide applicability among all FDA centers, and draws extensively on the well-vetted risk literature to define the relevant health dimensions for decision-making at the FDA. The report illustrates the use of that framework with several case studies, and provides conclusions and recommendations Introduction -- A Risk-Characterization Framework -- Case Study of a Mitigation-Selection Decision -- Case Study of a Targeting Decision -- Case Study of a Strategic-Investment Decision -- Case Study of a Targeting Decision That Spans Food and Drug Administration Centers -- Conclusions and Future Directions -- Letter Report on the Development of a Model for Ranking FDA Product Categories on the Basis of Health Risks -- Statement of Task for the Committee on Ranking FDA Product Categories Based on Health Consequences, Phase II -- Scenarios Provided by the U.S. Food and Drug Administration to the Committee on Ranking FDA Product Categories Based on Health Consequences, Phase II -- Biographic Information on the Committee on Ranking FDA Product Categories Based on Health Consequences, Phase II -- Factors Hypothesized as Important in Understanding Risk United States / Food and Drug Administration United States / Food and Drug Administration / Management United States / Food and Drug Administration fast United States Food and Drug Administration Case studies Consumer Product Safety Risk Assessment / methods Decision Making Drug Approval United States Government Agencies POLITICAL SCIENCE / Government / State & Provincial bisacsh Management fast Public health fast Decision making United States Case studies Product safety United States Decision making Case studies Risk assessment United States Case studies |
| subject_GND | (DE-588)4522595-3 |
| title | A risk-characterization framework for decision-making at the Food and Drug Administration |
| title_alt | Introduction -- A Risk-Characterization Framework -- Case Study of a Mitigation-Selection Decision -- Case Study of a Targeting Decision -- Case Study of a Strategic-Investment Decision -- Case Study of a Targeting Decision That Spans Food and Drug Administration Centers -- Conclusions and Future Directions -- Letter Report on the Development of a Model for Ranking FDA Product Categories on the Basis of Health Risks -- Statement of Task for the Committee on Ranking FDA Product Categories Based on Health Consequences, Phase II -- Scenarios Provided by the U.S. Food and Drug Administration to the Committee on Ranking FDA Product Categories Based on Health Consequences, Phase II -- Biographic Information on the Committee on Ranking FDA Product Categories Based on Health Consequences, Phase II -- Factors Hypothesized as Important in Understanding Risk |
| title_auth | A risk-characterization framework for decision-making at the Food and Drug Administration |
| title_exact_search | A risk-characterization framework for decision-making at the Food and Drug Administration |
| title_full | A risk-characterization framework for decision-making at the Food and Drug Administration Committee on Ranking FDA Product Categories Based on Health Consequences, Phase II, Board on Environmental Studies and Toxicolgoy, Division on Earth and Life Studies, National Research Council, Institute of Medicine, National Research Council of the National Academies |
| title_fullStr | A risk-characterization framework for decision-making at the Food and Drug Administration Committee on Ranking FDA Product Categories Based on Health Consequences, Phase II, Board on Environmental Studies and Toxicolgoy, Division on Earth and Life Studies, National Research Council, Institute of Medicine, National Research Council of the National Academies |
| title_full_unstemmed | A risk-characterization framework for decision-making at the Food and Drug Administration Committee on Ranking FDA Product Categories Based on Health Consequences, Phase II, Board on Environmental Studies and Toxicolgoy, Division on Earth and Life Studies, National Research Council, Institute of Medicine, National Research Council of the National Academies |
| title_short | A risk-characterization framework for decision-making at the Food and Drug Administration |
| title_sort | a risk characterization framework for decision making at the food and drug administration |
| topic | United States / Food and Drug Administration United States / Food and Drug Administration / Management United States / Food and Drug Administration fast United States Food and Drug Administration Case studies Consumer Product Safety Risk Assessment / methods Decision Making Drug Approval United States Government Agencies POLITICAL SCIENCE / Government / State & Provincial bisacsh Management fast Public health fast Decision making United States Case studies Product safety United States Decision making Case studies Risk assessment United States Case studies |
| topic_facet | United States / Food and Drug Administration United States / Food and Drug Administration / Management United States Food and Drug Administration Case studies Consumer Product Safety Risk Assessment / methods Decision Making Drug Approval United States Government Agencies POLITICAL SCIENCE / Government / State & Provincial Management Public health Decision making United States Case studies Product safety United States Decision making Case studies Risk assessment United States Case studies USA Fallstudiensammlung |
| url | http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=372484 |
| work_keys_str_mv | AT nationalacademiesuscommitteeonrankingfdaproductcategoriesbasedonhealthconsequencesphaseii ariskcharacterizationframeworkfordecisionmakingatthefoodanddrugadministration |